MAPK3 and diabetes mellitus: Both empagliflozin-treated and liraglutide-treated DM hearts exhibited significantly decreased protein levels of phosphorylated extracellular signal-regulated kinase 1/2 (pERK1/2) (Figure 5c) compared with DM rats.